ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Resveratrol-loaded novasomal gel for sustained dermal delivery against monobenzone-induced vitiligo-like depigmentation in black chicks.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitiligo is a multifactorial depigmenting disorder characterized by melanocyte loss, oxidative stress, and impaired melanogenesis. Resveratrol (RVT) exhibits potent antioxidant and cytoprotective properties; however, its topical application is limited by its poor cutaneous penetration, rapid degradation, and limited local bioavilability. To overcome these limitations, we developed a resveratrol-loaded novasomal formulation (RVT-NVS) and evaluated its physicochemical properties, in vitro release behavior, repigmentation efficacy in a 40% monobenzone (MZ)-induced vitiligo-like depigmentation model in black chicks. Dermal tolerability was additionally assessed in rats. RVT-NVS exhibited nanoscale vesicles with an average size of 386 nm, a a relatively narrow size distribution (PDI = 0.31), high entrapment efficiency of 79%, and a negative zeta potential of - 37 mV. The RVT-NVS gel showed sustained RVT release over 12 h compared with the free RVT gel. MZ induced marked depigmentation, hematological alterations, reduced body weight gain, histopathological skin damage, reduced tyrosinase immunoreactivity, and altered behavioral readouts. RVT-NVS significantly improved visible repigmentation, normalized hematological parameters, improved body weight gain, preserved epidermal and feather follicle architecture, and restored tyrosinase-positive melanocyte-associated staining more effectively than free RVT, blank nanovehicle, or natural composite formulations. RVT-NVS also improved several MZ-associated behavioral readouts, including sweet-solution consumption, locomotor activity, social-response measures, freezing behavior, and tonic immobility duration. Molecular docking suggested possible interactions of RVT with targets related to redox regulation, melanogenesis, inflammation, and apoptosis, with favorable predicted interactions observed for catalase (CAT) and selected melanogenesis-associated targets. These findings suggest that RVT-NVS may represent a promising nanoscale topical delivery system for chemically induced oxidative melanocyte injury and vitiligo-like depigmentation.
Indexed as
Identifiers
42365115What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.